Abacus FCF Advisors LLC trimmed its stake in DaVita Inc. (NYSE: DVA) by 60.3% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,677 shares of the company's stock after selling 23,857 shares during the period. Abacus FCF Advisors

In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $116.51, denoting a +1.14% move from the preceding trading day.

Board of the Pension Protection Fund purchased a new position in shares of DaVita Inc. (NYSE: DVA) during the undefined quarter, according to its most recent 13F filing with the SEC. The firm purchased 6,400 shares of the company's stock, valued at approximately $850,000. Other hedge funds and other institutional investors have also

An aging population and rising AI adoption position the Zacks Medical - Outpatient and Home Healthcare industry for solid growth. EHC, DVA, OPCH and PNTG stand to benefit.

DVA stock gets support from a patient-centric model, Q3 revenue growth and overseas expansion, even as reliance on commercial payers remains a risk.

California Public Employees Retirement System decreased its position in shares of DaVita Inc. (NYSE: DVA) by 22.9% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 153,815 shares of the company's stock after selling 45,576 shares during the period.

Appointments of Chief People Officer and Chief Strategy Officer underscore commitment to innovation and people-first approach DENVER , Dec. 11, 2025 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced two key additions to its executive leadership team: Stephanie Hendrickson has been named Chief People Officer (CPO) and Steve Phillips will serve as Chief Strategy Officer (CSO), effective immediately. Both leaders bring more than a decade of proven success at DaVita and deep expertise that will help shape the company's next chapter of growth and innovation.

DaVita (DVA) is rated a speculative 'Buy,' reflecting undervaluation despite recent earnings volatility. DVA's moat stems from its dominant US dialysis clinic network, but its reliance on Medicare reimbursement and lack of dividend heighten risk. Trading below 11.5x P/E, DVA offers potential double-digit annual returns if it reverts to historical valuation multiples.

Edgestream Partners L.P. purchased a new stake in shares of DaVita Inc. (NYSE: DVA) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 44,754 shares of the company's stock, valued at approximately $6,375,000. Edgestream Partners L.P. owned approximately 0.06% of DaVita at

Hsbc Holdings PLC lowered its holdings in DaVita Inc. (NYSE: DVA) by 4.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 144,780 shares of the company's stock after selling 6,138 shares during the period. Hsbc Holdings PLC owned approximately 0.20% of